Figure 1
Figure 1. Activation of peripheral blood pDCs with aPLs. pDCs were incubated with HL5B, HL7G, RR7F, or irrelevant IgG. (A) Time course (left) and dose response curve after 1 hour (right) are shown. Relative expression of TLR7 mRNA was determined by quantitative RT-PCR normalized to β-actin. Values represent mean ± SD of at least 5 independent experiments. *P < .02 and **P < .001 for aPLs versus IgG. (B) Relative expression of IFNα (left) and TNFα (right) mRNA normalized to β-actin. Values represent mean ± SD of at least 5 independent experiments. *P < .01, **P < .001 for HL5B versus IgG. (C) Effect of inhibition of IFNα by BDCA-2 (1 μg/mL; left) or inhibition of TNFα by adalimumab (0.1 μg/mL; right) on TLR7 expression. *P < .03 for HL5B versus HL5B plus inhibitor. (D) Effect of inhibition of NFκB by Ro106-9920 (5μM). Expression of TLR7 (left) and IFNα (right, solid line) or TNFα (right, dotted line). *P < .03, **P < .001 for HL5B versus HL5B plus inhibitor.

Activation of peripheral blood pDCs with aPLs. pDCs were incubated with HL5B, HL7G, RR7F, or irrelevant IgG. (A) Time course (left) and dose response curve after 1 hour (right) are shown. Relative expression of TLR7 mRNA was determined by quantitative RT-PCR normalized to β-actin. Values represent mean ± SD of at least 5 independent experiments. *P < .02 and **P < .001 for aPLs versus IgG. (B) Relative expression of IFNα (left) and TNFα (right) mRNA normalized to β-actin. Values represent mean ± SD of at least 5 independent experiments. *P < .01, **P < .001 for HL5B versus IgG. (C) Effect of inhibition of IFNα by BDCA-2 (1 μg/mL; left) or inhibition of TNFα by adalimumab (0.1 μg/mL; right) on TLR7 expression. *P < .03 for HL5B versus HL5B plus inhibitor. (D) Effect of inhibition of NFκB by Ro106-9920 (5μM). Expression of TLR7 (left) and IFNα (right, solid line) or TNFα (right, dotted line). *P < .03, **P < .001 for HL5B versus HL5B plus inhibitor.

Close Modal

or Create an Account

Close Modal
Close Modal